CVE-2023-27167

CVE-2023-27167 is a medium-severity vulnerability in Supremainc Biostar 2 with a CVSS 3.x base score of 6.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-89.

Key facts

Description

Suprema BioStar 2 v2.8.16 was discovered to contain a SQL injection vulnerability via the values parameter at /users/absence?search_month=1.

Frequently asked questions

What is CVE-2023-27167?
Suprema BioStar 2 v2.8.16 was discovered to contain a SQL injection vulnerability via the values parameter at /users/absence?search_month=1.
How severe is CVE-2023-27167?
CVE-2023-27167 has a CVSS 3.x base score of 6.5, rated medium severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity none, and availability none.
Is CVE-2023-27167 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 7% (94th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-27167?
CVE-2023-27167 affects Supremainc Biostar 2. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-27167?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
When was CVE-2023-27167 published?
CVE-2023-27167 was published on 2023-03-29 and last updated on 2026-07-05.

References

Affected products (1)

More vulnerabilities in Supremainc Biostar 2

All CVEs affecting Supremainc Biostar 2 →

Other CWE-89 (SQL Injection) vulnerabilities

Browse all CWE-89 (SQL Injection) vulnerabilities →